Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)

Peng, Zhenwei; Fan, Wenzhe; Zhu, Bowen; Wang, Guoying; Sun, Junhui; Xiao, Chengjiang; Huang, Fuxi; Tang, Rong; Cheng, Yu; Huang, Zhen; Liang, Yuchuang; Fan, Huishuang; Qiao, Liangliang; Li, Fuliang; Zhuang, Wenquan; Peng, Baogang; Wang, Jiping; Li, Jiaping; Kuang, Ming

doi:10.1200/jco.22.00392

Public

Lenvatinib Combined With Transarterial Chemoembolization as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Phase III, Randomized Clinical Trial (LAUNCH)

Published in Journal of Clinical Oncology • Aug 3, 2022

Authors:

Zhenwei Peng

Wenzhe Fan

Bowen Zhu

Abstract

PURPOSE Lenvatinib (LEN) is a first-line therapy for patients with advanced hepatocellular carcinoma (HCC); however, it has shown modest survival benefits. Therefore, we aimed to compare clinical outcomes of LEN combined with transarterial chemoembolization (LEN-TACE) versus LEN monotherapy in patie...

Subject

Medicine

Hazard ratio

Hepatocellular carcinoma

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!